GSA Capital Partners’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.53M | Sell |
21,331
-1,783
| -8% | -$102K | 0.1% | 270 |
|
|
2025
Q4 | $977K | Buy |
+23,114
| New | +$1.29M | 0.08% | 371 |
|
|
2024
Q4 | – | Sell |
-14,283
| Closed | -$279K | – | 1884 |
|
|
2024
Q3 | $279K | Sell |
14,283
-47,780
| -77% | -$911K | 0.02% | 1255 |
|
|
2024
Q2 | $1.15M | Sell |
62,063
-70,597
| -53% | -$1.49M | 0.08% | 414 |
|
|
2024
Q1 | $1.86M | Sell |
132,660
-217,726
| -62% | -$2.28M | 0.15% | 140 |
|
|
2023
Q4 | $2.97M | Buy |
350,386
+227,647
| +185% | +$1.72M | 0.25% | 33 |
|
|
2023
Q3 | $1.1M | Buy |
122,739
+110,840
| +932% | +$1.07M | 0.09% | 348 |
|
|
2023
Q2 | $103K | Sell |
11,899
-125
| -1% | -$1.33K | 0.01% | 1378 |
|
|
2023
Q1 | $127K | Sell |
12,024
-30,978
| -72% | -$937K | 0.01% | 1328 |
|
|
2022
Q4 | $1.46M | Buy |
43,002
+39,050
| +988% | +$1.89M | 0.18% | 74 |
|
|
2022
Q3 | $190K | Buy |
3,952
+1,257
| +47% | +$74.8K | 0.03% | 1241 |
|
|
2022
Q2 | $154K | Buy |
+2,695
| New | +$170K | 0.02% | 1137 |
|
|
2022
Q1 | – | Sell |
-702
| Closed | -$142K | – | 1693 |
|
|
2021
Q4 | $142K | Sell |
702
-804
| -53% | -$174K | 0.02% | 1280 |
|
|
2021
Q3 | $406K | Sell |
1,506
-4,338
| -74% | -$1.04M | 0.04% | 824 |
|
|
2021
Q2 | $1.5M | Buy |
+5,844
| New | +$1.62M | 0.17% | 122 |
|
|
2020
Q4 | – | Sell |
-1,994
| Closed | -$496K | – | 1477 |
|
|
2020
Q3 | $496K | Buy |
+1,994
| New | +$627K | 0.08% | 394 |
|
|
2018
Q4 | – | Sell |
-1,049
| Closed | -$959K | – | 1611 |
|
|
2018
Q3 | $959K | Sell |
1,049
-57
| -5% | -$48.7K | 0.05% | 706 |
|
|
2018
Q2 | $810K | Buy |
+1,106
| New | +$1.28M | 0.04% | 881 |
|
|
2018
Q1 | – | Sell |
-949
| Closed | -$850K | – | 1759 |
|
|
2017
Q4 | $850K | Sell |
949
-3,091
| -77% | -$1.83M | 0.05% | 676 |
|
|
2017
Q3 | $1.45M | Buy |
+4,040
| New | +$1.26M | 0.1% | 298 |
|
|
2017
Q1 | – | Sell |
-1,674
| Closed | -$308K | – | 1911 |
|
|
2016
Q4 | $308K | Buy |
+1,674
| New | +$340K | 0.02% | 1319 |
|
|
2016
Q2 | – | Sell |
-1,781
| Closed | -$367K | – | 1850 |
|
|
2016
Q1 | $367K | Sell |
1,781
-580
| -25% | -$111K | 0.02% | 1200 |
|
|
2015
Q4 | $597K | Sell |
2,361
-658
| -22% | -$135K | 0.03% | 1044 |
|
|
2015
Q3 | $496K | Sell |
3,019
-4,820
| -61% | -$853K | 0.02% | 1127 |
|
|
2015
Q2 | $1.47M | Sell |
7,839
-441
| -5% | -$75.9K | 0.06% | 588 |
|
|
2015
Q1 | $1.37M | Buy |
8,280
+5,618
| +211% | +$1.15M | 0.05% | 629 |
|
|
2014
Q4 | $619K | Sell |
2,662
-1,429
| -35% | -$305K | 0.04% | 789 |
|
|
2014
Q3 | $741K | Buy |
4,091
+2,570
| +169% | +$492K | 0.04% | 685 |
|
|
2014
Q2 | $293K | Buy |
+1,521
| New | +$269K | 0.01% | 1436 |
|
Other funds holding NKTR
BI
TSC
VCM
PM
AC
GSA Capital Partners's NKTR Position: Q1 2026 in Review
GSA Capital Partners reduced its Nektar Therapeutics (NKTR) stake by 7.7% in Q1 2026, selling an estimated $102K and leaving 21,331 shares worth $1.53M. The position accounts for 0.1% of the portfolio, ranked #270.
GSA Capital Partners first reported a position in NKTR in Q2 2014 and has held it in 29 quarters since. The position peaked at $2.97M in Q4 2023. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.
- GSA Capital Partners held 21,331 shares of Nektar Therapeutics worth $1.53M as of Q1 2026.
- GSA Capital Partners sold 1,783 Nektar Therapeutics shares in Q1 2026, an estimated $102K.
- Nektar Therapeutics made up 0.1% of GSA Capital Partners's portfolio in Q1 2026, its #270 holding.
- GSA Capital Partners first reported a position in Nektar Therapeutics in Q2 2014 and has held it in 29 quarters since.
- GSA Capital Partners's Nektar Therapeutics position peaked at $2.97M in Q4 2023.
- 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.
Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.